Secondary goals include evaluating the combined impact on inhibiting cancer cell growth, measuring insulin/PI3K pathway activation, assessing changes in weight and body composition, and determining the efficacy of inducing a ketogenic state in synergy with endocrine therapy. The gene discussed is PIK3CG; the disease is cancer.